litlas
ログインアカウント作成

Amy J. Johnson

1978–2025 年に発表

73
論文数
18,930
被引用数
59
h 指数
71
i10 指数

被引用数

Amy J. Johnson の年別被引用数1978 年: 被引用 1 件1979 年: 被引用 4 件1980 年: 被引用 1 件1981 年: 被引用 4 件1982 年: 被引用 2 件1983 年: 被引用 3 件1984 年: 被引用 1 件1985 年: 被引用 3 件1986 年: 被引用 2 件1987 年: 被引用 3 件1989 年: 被引用 3 件1990 年: 被引用 2 件1991 年: 被引用 1 件1995 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 4 件2003 年: 被引用 3 件2004 年: 被引用 9 件2005 年: 被引用 9 件2006 年: 被引用 8 件2007 年: 被引用 14 件2008 年: 被引用 28 件2009 年: 被引用 63 件2010 年: 被引用 66 件2011 年: 被引用 87 件2012 年: 被引用 119 件2013 年: 被引用 186 件2014 年: 被引用 288 件2015 年: 被引用 386 件2016 年: 被引用 319 件2017 年: 被引用 326 件2018 年: 被引用 330 件2019 年: 被引用 938 件2020 年: 被引用 879 件2021 年: 被引用 947 件2022 年: 被引用 523 件2023 年: 被引用 360 件2024 年: 被引用 526 件2025 年: 被引用 236 件2026 年: 被引用 11 件1988 年は被引用が無いため表示していません1992〜1994 年は被引用が無いため表示していません1996〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,002 件、この内訳の 30.1%中国: 引用元論文 575 件、この内訳の 8.6%イギリス: 引用元論文 490 件、この内訳の 7.4%ドイツ: 引用元論文 427 件、この内訳の 6.4%イタリア: 引用元論文 375 件、この内訳の 5.6%フランス: 引用元論文 266 件、この内訳の 4%スペイン: 引用元論文 225 件、この内訳の 3.4%オーストラリア: 引用元論文 223 件、この内訳の 3.4%カナダ: 引用元論文 204 件、この内訳の 3.1%オランダ: 引用元論文 152 件、この内訳の 2.3%スイス: 引用元論文 148 件、この内訳の 2.2%スウェーデン: 引用元論文 116 件、この内訳の 1.7%
0%30.1%その他 21.8%

機関

分野

  • Medicine64.8%
  • Biochemistry, Genetics and Molecular Biology26.9%
  • Immunology and Microbiology4%
  • Chemistry1.7%
  • Neuroscience0.7%
  • Computer Science0.6%
  • その他1.3%

トピック

  • Chronic Lymphocytic Leukemia Research15.2%
  • Lymphoma Diagnosis and Treatment10%
  • CAR-T cell therapy research4.5%
  • Protein Degradation and Inhibitors3.9%
  • Immunodeficiency and Autoimmune Disorders3.6%
  • Chronic Myeloid Leukemia Treatments3%
  • その他59.8%

共著者

全論文

検索で開く
  1. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    著者: Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gülçin Özer, Marc Zapatka, Amy S. Ruppert, Ling Xue, Daniel Hsieh-Hsin Li, Susanne Steggerda, Matthias Versele, Sandeep S. Davé, Jenny Zhang, Ayse Selen Yilmaz, Samantha Jaglowski, Kristie A. Blum, Arletta Lozanski, Gerard Lozanski, Danelle F. James, Jacqueline C. Barrientos, Peter Lichter, Stephan Stilgenbauer, Joseph J. Buggy, Betty Chang, Amy J. Johnson, John C. Byrd - New England Journal of Medicine 2014 被引用: 1,254

  2. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation

    著者: Alexandru D. Buhimschi, Haley A. Armstrong, Momar Toure, Saul Jaime‐Figueroa, Timothy L. Chen, Amy M. Lehman, Jennifer A. Woyach, Amy J. Johnson, John C. Byrd, Craig M. Crews - Biochemistry 2018 被引用: 372

  3. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 被引用: 2,249

  4. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

    著者: Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn, Amy Lehman, James S. Blachly, Arletta Lozanski, Nyla A. Heerema, Weiqiang Zhao, Joshua F. Coleman, Daniel Jones, Lynne V. Abruzzo, Amber Gordon, Rose Mantel, Lisa L. Smith, Samantha McWhorter, Melanie E. Davis, Tzyy-Jye Doong, Fan Ny, Margaret S. Lucas, Weihong Chase, Jeffrey A. Jones, Joseph M. Flynn, Kami J. Maddocks, Kerry A. Rogers, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Gerard Lozanski, Amy J. Johnson, John C. Byrd - Journal of Clinical Oncology 2017 被引用: 471

  5. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    著者: John C. Byrd, Bonnie K. Harrington, Susan O’Brien, Jeffrey A. Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G. Wierda, Farrukh T. Awan, Jennifer R. Brown, Peter Hillmen, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, John M. Pagel, Jennifer A. Woyach, Dave Johnson, Jane Huang, Xiaolin Wang, Allard Kaptein, Brian J. Lannutti, Todd Covey, Maria Fardis, Jesse McGreivy, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Thomas G. Diacovo, Amy J. Johnson, Richard R. Furman - New England Journal of Medicine 2015 被引用: 891

  6. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

    著者: Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua Hessler, Ta-Ming Liu, Betty Chang, Karilyn M. Larkin, Matthew Stefanovski, Danielle L. Chappell, Frank Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami J. Maddocks, Amy M. Lehman, Richard R. Furman, Jeff P. Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd - Blood 2013 被引用: 796

  7. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

    著者: Sarah E. M. Herman, Amber Gordon, Erin Hertlein, Asha Ramanunni, Xiaoli Zhang, Samantha Jaglowski, Joseph M. Flynn, Jeffrey J. Jones, Kristie A. Blum, Joseph J. Buggy, Ahmed Hamdy, Amy J. Johnson, John C. Byrd - Blood 2011 被引用: 791

  8. DNA Origami Nanostructures Elicit Dose‐Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo

    著者: Christopher R. Lucas, Patrick D. Halley, Amjad A. Chowdury, Bonnie K. Harrington, Larry Beaver, Rosa Lapalombella, Amy J. Johnson, Erin Hertlein, Mitch A. Phelps, John C. Byrd, Carlos E. Castro - Small 2022 被引用: 103

  9. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

    著者: Kami J. Maddocks, Amy S. Ruppert, Gerard Lozanski, Nyla A. Heerema, Weiqiang Zhao, Lynne V. Abruzzo, Arletta Lozanski, Melanie E. Davis, Amber Gordon, Lisa L. Smith, Rose Mantel, Jeffrey A. Jones, Joseph M. Flynn, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Amy J. Johnson, John C. Byrd, Jennifer A. Woyach - JAMA Oncology 2015 被引用: 576

  10. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

    著者: Joseph A. Fraietta, Kyle A. Beckwith, Prachi Patel, Marco Ruella, Zhaohui Zheng, David M. Barrett, Simon F. Lacey, J. Joseph Melenhorst, Shannon E. McGettigan, Danielle Cook, Changfeng Zhang, Jun Xu, Priscilla Do, Jessica Hulitt, Sagar B. Kudchodkar, Alexandria P. Cogdill, Saar Gill, David L. Porter, Jennifer A. Woyach, Meixiao Long, Amy J. Johnson, Kami J. Maddocks, Natarajan Muthusamy, Bruce L. Levine, Carl H. June, John C. Byrd, Marcela V. Maus - Blood 2016 被引用: 461

  11. Ibrutinib treatment improves T cell number and function in CLL patients

    著者: Meixiao Long, Kyle A. Beckwith, Priscilla Do, Bethany L. Mundy-Bosse, Amber Gordon, Amy M. Lehman, Kami J. Maddocks, Carolyn Cheney, Jeffrey A. Jones, Joseph M. Flynn, Leslie A. Andritsos, Farrukh T. Awan, Joseph A. Fraietta, Carl H. June, Marcela V. Maus, Jennifer A. Woyach, Michael A. Caligiuri, Amy J. Johnson, Natarajan Muthusamy, John C. Byrd - Journal of Clinical Investigation 2017 被引用: 377

  12. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug

    著者: Alan G. Ramsay, Amy J. Johnson, Abigail M. Lee, Güllü Görgün, Rifca Le Dieu, William Blum, John C. Byrd, John G. Gribben - Journal of Clinical Investigation 2008 被引用: 594

  13. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

    著者: Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph M. Flynn, Leslie A. Andritsos, Kami J. Maddocks, Samantha Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson - Blood 2015 被引用: 174

  14. The B-cell receptor signaling pathway as a therapeutic target in CLL

    著者: Jennifer A. Woyach, Amy J. Johnson, John C. Byrd - Blood 2012 被引用: 409

  15. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O’Brien - Blood 2015 被引用: 656

  16. Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice

    著者: Satomi Miwa, Howsun Jow, Karen Baty, Amy J. Johnson, Rafal Czapiewski, Gabriele Saretzki, Achim Treumann, Thomas von Zglinicki - Nature Communications 2014 被引用: 214

  17. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

    著者: Sean D. Reiff, Rose Mantel, Lisa L. Smith, J.T. Greene, Elizabeth M. Muhowski, Catherine A. Fabian, Virginia M. Goettl, Minh Tran, Bonnie K. Harrington, Kerry A. Rogers, Farrukh T. Awan, Kami J. Maddocks, Leslie A. Andritsos, Amy M. Lehman, Deepa Sampath, Rosa Lapalombella, Sudharshan Eathiraj, Giovanni Abbadessa, Brian Schwartz, Amy J. Johnson, John C. Byrd, Jennifer A. Woyach - Cancer Discovery 2018 被引用: 170

  18. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

    著者: Brian J. Lannutti, Sarah Meadows, Sarah E. M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey Tyner, Marc Loriaux, Mike Deininger, Brian Druker, Kamal D. Puri, Roger G. Ulrich, Neill A. Giese - Blood 2010 被引用: 718

  19. Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma

    著者: David Chiron, Maurizio Di Liberto, Peter Martin, Xiangao Huang, Jeff P. Sharman, Pedro Blecua, Susan Mathew, Priyanka Vijay, Ken Eng, Siraj M. Ali, Amy J. Johnson, Betty Chang, Scott Ely, Olivier Elemento, Christopher E. Mason, John P. Leonard, Selina Chen‐Kiang - Cancer Discovery 2014 被引用: 272

  20. Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

    著者: Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert, Matthew Stefanovski, Virginia M. Goettl, Kelly A. Smucker, Lisa L. Smith, Jason A. Dubovsky, William H. Towns, Jessica MacMurray, Bonnie K. Harrington, Melanie E. Davis, Stefania Gobessi, Luca Laurenti, Betty Chang, Joseph J. Buggy, Dimitar G. Efremov, John C. Byrd, Amy J. Johnson - Blood 2013 被引用: 219

  21. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

    著者: Rosa Lapalombella, Qingxiang Sun, Katie Williams, Larissa Tangeman, Shruti Jha, Yiming Zhong, Virginia M. Goettl, Emilia Mahoney, Caroline Berglund, Sneha Gupta, Alicia Farmer, Rajeswaran Mani, Amy J. Johnson, David Lucas, Xiaokui Mo, Dirk Daelemans, Vincent Sandanayaka, Sharon Shechter, Dilara McCauley, Sharon Shacham, Michael Kauffman, Yuh Min Chook, John C. Byrd - Blood 2012 被引用: 297

  22. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

    著者: Susan O’Brien, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd - Blood 2018 被引用: 387

  23. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling

    著者: Yuh-Ying Yeh, Hatice Gülçin Özer, Amy M. Lehman, Kami J. Maddocks, Lianbo Yu, Amy J. Johnson, John C. Byrd - Blood 2015 被引用: 159

  24. Genetic heterogeneity of diffuse large B-cell lymphoma

    著者: Jenny Zhang, Vladimir Grubor, Cassandra Love, Anjishnu Banerjee, Kristy L. Richards, Piotr A. Mieczkowski, Cherie H. Dunphy, William Choi, Wing Y. Au, Gopesh Srivastava, Patricia Lugar, David A. Rizzieri, Anand S. Lagoo, Leon Bernal‐Mizrachi, Karen P. Mann, Christopher R. Flowers, Kikkeri N. Naresh, Andrew M. Evens, Leo I. Gordon, Magdalena Czader, Javed Gill, Eric D. Hsi, Qingquan Liu, Alice C. Fan, Katherine H. Walsh, Dereje D. Jima, Lisa L. Smith, Amy J. Johnson, John C. Byrd, Micah A. Luftig, Ting Ni, Jun Zhu, Amy Chadburn, Shawn Levy, David B. Dunson, Sandeep S. Davé - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 被引用: 534